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Abstract
Introduction We have previously shown that children who
developed de novo donor-specific human leukocyte antigen
(HLA) antibodies (DSA) had greater decline in allograft func-
tion. We hypothesised that patients with complement-
activating DSAwould have poorer renal allograft outcomes.
Methods A total of 75 children developed DSA in the original
study. The first positive DSA sample was subsequently tested
for C1q and C3d fixing. The primary event was defined as
50% reduction from baseline estimated glomerular filtration
rate and was analysed using the Kaplan–Meier estimator.
Results Of 65 patients tested, 32 (49%) and 23 (35%) tested
positive for C1q and C3d fixing, respectively. Of the 32 C1q-
positive (c1q+) patients, 13 (41%) did not show concomitant
C3d fixing. The mean fluorescence intensity values of the
original immunoglobulin G DSA correlated poorly with
complement-fixing positivity (C1q: adjusted R2 0.072; C3d:
adjusted R2 0.11; p < 0.05). C1q+ antibodies were associated
with acute tubulitis [0.75 ± 0.18 (C1q+) vs. 0.25 ± 0.08 (C1q
−) episodes per patient (mean ± standard error of the mean;
p < 0.05] but not with worse long-term renal allograft dys-
function (median time to primary event 5.9 (C1q+) vs. 6.4
(C1q−) years; hazard ratio (HR) 0.74; 95% confidence ratio
(CI) 0.30–1.81; p = 0.58]. C3d-positive (C3d+) antibodies
were associated with positive C4d histological staining [47%
(C3d+) vs. 20% (C3d−); p = 0.04] and with significantly
worse long-term allograft dysfunction [median time to prima-
ry event: 5.6 (C3d+) vs. 6.5 (C3d−) years; HR 0.38; 95% CI
0.15–0.97; p = 0.04].
Conclusion Assessment of C3d fixing as part of prospective
HLAmonitoring can potentially aid stratification of patients at
the highest risk of long-term renal allograft dysfunction.
Keywords Renal transplant . HLA antibodies .
Donor-specific antibodies . Complement fixation . Prognosis
Introduction
Children represent a group of patients with low levels of sen-
sitisation against human leukocyte antigens (HLA) as they
have generally not been previously exposed to multiple blood
products, pregnancies or previous transplants [1]. However,
they do have a more naive immune compartment and are
prone to developing infections which carry a small risk of
cross-reaction with the allograft through heterologous immu-
nity [2]. Children face lifelong immunosuppression and po-
tential multiple re-transplants. Therefore, finding the correct
balance between the suppression of alloimmunity and the side
effects of immunosuppression is even more important [3].
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We previously published the largest cohort of paediatric
renal transplant recipients screened prospectively for de novo
donor-specific HLA antibodies (DSA) [4]. DSA-positive pa-
tients were found to have a faster decline in allograft function
and more features of antibody-mediated rejection (AMR) on
biopsies done ‘for-cause’. Also, the level of allograft dysfunc-
tion correlated with rising mean fluorescence intensity (MFI)
levels for Class II DSA. In the study reported here, we inves-
tigated further the capability of DSA to activate the comple-
ment cascade through in vitro assays detecting complement
binding at the levels of C1q (first subcomponent of the C1
complex of the classical pathway of complement activation)
and C3d (subcomponent of complement component 3) [5, 6].
We hypothesised that patients with complement-activating
DSAwould have poorer renal allograft outcomes.
Materials and methods
Study design
Patients who tested positive for DSA (DSA+) were identified
from our previously published single-centre cohort study [4].
In brief, all renal transplant recipients from 1 January 2006
(existing and new transplants after this date) were screened
prospectively (1–3, 6, 12 months post-transplant and annually
thereafter) using OneLambda assays (One Lambda, Canoga
Park, CA) and pan-immunoglobulin G (IgG) secondary anti-
body. The cumulative frequency of the antibody tests was 60,
86 and 98% at 3, 6 and 12 months, respectively. All sera were
heat inactivated in a water bath at 56 °C for 30 min to alleviate
prozone effects. No thresholdMFI for positive DSAwas set as
an a priori criteria.
In this study, the first DSA-positive serum was further test-
ed for complement binding capabilities (Fig. 1a). Clinical
characteristics were as previously described. Follow-up esti-
mated glomerular filtration rate (eGFR, calculated using
Schwartz formula) data were extended until April 2015.
Immunosuppression data were obtained at the time of DSA
detection. Histological classification was based on the Banff
2009 criteria.
C1q and C3d detection assays
Experiments were performed by researchers blinded to patient
information at the Clinical Transplantation Laboratory,
Viapath, Guy’s Hospital, London, in a single run and using
assays from the same batch. Patients were defined as ‘com-
plement positive’ if at least one DSA showed complement
fixing.
C1q-binding DSA were identified using C1qScreen™
(One Lambda) according to the manufacturer’s protocol [5].
Sera were pre-treated with heat inactivation of the
complement system as part of the protocol. Analysis was per-
formed using the HLA Fusion 2.0 software (One Lambda).
Complement positivity was assigned at >1000 MFI based on
the negative control sera and internal negative control beads.
C3d-binding DSAwere identified using Lifecodes C3d and
Single Antigen assay (Immucor, London, UK) according to
the manufacturer’s protocol [6]. In addition, sera were tested
for pan-IgG using Lifecodes Single Antigen kits (Immucor).
Results were analysed using the same manufacturer’s MatchIt
software, and complement positivity was defined as per the
software algorithm.
Statistical analysis
Data were presented as the mean ± standard error of the mean)
and as the median with the interquartile range (IQR), as ap-
propriate. Comparisons between groups were performed with
the Mann–Whitney test, and comparisons of proportions were
performed using the Fischer and chi-square tests. Correlation
between IgG MFI and complement positivity was estimated
using logistic regression. Event-free survival was estimated
with the Kaplan–Meier method and was compared between
risk groups using the log-rank test. The primary event was
defined as a sustained 50% reduction (defined as two consec-
utive results at least 3 months apart) from baseline eGFR as
per the previous study results, and patients were censored at
the end of the follow-up period [3]. Statistical analysis was
performed using GraphPad Prism 5.0 (GraphPad Software
Inc., LaJolla, CA), with p values of <0.05 considered to be
significant. Multilevel linear modelling was performed using
‘nlme’ on the R statistical platform [7]. The model used indi-
vidual patient nesting and fixed effect of follow-up time as
described in our previous study [4]. The associations investi-




In our original cohort, 215 patients underwent prospective
screening for HLA antibodies (at 1–3, 6, 12 months and an-
nually thereafter), using the LABScreen Mixed screening tool
followed by screening with the Single Antigen Beads (SAB)
assay from OneLambda. Of these 215 patients, 75 tested pos-
itive for IgG DSA at a median time of 0.25 years post-trans-
plant. Serum samples for 65 of these 75 patients were avail-
able for further testing, and the first positive DSA sample was
tested using the C1q and C3d assays (Fig. 1a); serum samples
for the remaining ten patients were unavailable due to these
patients, and their sera, transferring to adult centres out of the
region. This latter group of ten patients represented an older
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group (median age of transplant 13.7 years) with more cellular
rejection [Electronic Supplementary Material (ESM) Table 1],
of whom six met the primary outcome of 50% reduction from
baseline eGFR. Using the C1q assay, 32 of the 65 (49%)
patients included in the study tested positive for the following
DSA: HLA-A (n = 5), HLA-B (n = 8), HLA-C (n = 2), HLA-
DQ (n = 22) and HLA-DR (n = 4). Using the C3d assay, 23 of
the 65 (35%) patients tested positive for the following DSA:
HLA-A (n = 3), HLA-B (n = 5), HLA-DQ (n = 14) and HLA-
DR (n = 4). The breakdown of HLA types according to the
C1q and C3d assays was similar to that according to the whole
DSA+ cohort assay (Table 1). Serum samples tested later post-
transplant showed a tendency towards positive complement
(C1q+/C3d+) results, although this trend was not statistically
significant [Table 2 (median): 2.6 (C1q+) vs. 0.4 (C1q−)
years, p = 0.17; 2.3 (C3d+) vs. 0.4 (C3d−) years, p = 0.28].
Higher total IgG MFI was observed for patients who had
C1q+ DSA compared to those who had C1q− (mean ± SEM
4968 ± 1492 vs. 3006 ± 607, p < 0.005; Fig. 2) based on the
original pan-IgG antibody identification. Nonetheless, there
was a large overlap between MFI values and a poor correla-
tion between IgG MFI and C1q results (adjusted R2 = 0.072).
Similarly, higher total IgGMFI was observed for patients with
C3d+ DSA than for those with C3d− DSA (9483 ± 2289 vs.
4184 ± 648, p < 0.005) on the original OneLambda pan-IgG
antibody identification; however, there was a poor correlation
between IgG MFI and the C3d results (adjusted R2 = 0.11).
There was no difference between total IgG MFI in C1q− and
C3d− patients, or in C1q+ and C3d+ patients. Therefore, it
would appear that IgG MFI is not a significant predictor of
DSA complement binding capabilities.
Comparison of the C1q and C3d results revealed that 19
patients were C1q+/C3d+, 13 patients were C1q+/C3d− and
four patients were C3d+/C1q− (Fig. 1b). Therefore, a large
proportion of patients with positive C1q binding did not show
concomitant C3d binding (13/32, 41%). The breakdown of
individual DSA classes are as shown in Table 1. There was
a better concordance between C1q and C3d binding for Class
Table 1 Human leukocyte antigen types of C1q+ and C3d+ antibodies
compared to the overall DSA+ cohort
HLA group C1q+ C3d+ DSA+
HLA-A 5 (11%) 3 (12%) 16 (17%)
HLA-B 8 (20%) 5 (19%) 21 (22%)
HLA-C 2 (5%) 0 7 (8%)
HLA-DP 0 0 1 (1%)
HLA-DQ 22 (54%) 14 (54%) 34 (37%)
HLA-DR 4 (10%) 4 (15%) 14 (15%)
p = 0.5, Chi-square test
C1q, First subcomponent of the C1 complex of the classical pathway of
complement activation; C3d, subcompent of complement component 3
C3; HLA, human leukocyte antigen; IgG, immunoglobulin G; DSA,
donor-specific HLA antibodies
Fig. 1 aGraphical representation
of study design. b Venn diagram
showing overlap between C1q
(first subcomponent of the C1
complex of the classical pathway
of complement activation) and
C3d (subcomponent of
complement component 3 C3)
assay. Numbers indicate the
number of Class I/Class II pa-
tients. HLA human leukocyte an-
tigen, IgG immunoglobulin G,
DSA donor-specific antibodies to
human leukocyte antigen (HLA)
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II DSA. As the single antigen beads differ due the different
manufacturers of the C1q and C3d assays, all sera were retested
for DSA IgG binding using the SAB assay from the C3d man-
ufacturer in order to confirm antibody detection and to rule out
the detection of potential false positives due to the differing
manufacturing methods between the kits. For C1q+/C3d− pa-
tients, 17/22 (77%) DSA IgG specificities were detected using
the assays of both manufacturers. For C1q−/C3d+ patients, 3/7
(43%) DSA IgG specificities were detected using the assays of
both manufacturers. Of note, there were no samples which were
positive for complement binding and negative for DSA IgG
detection, suggesting that no non-IgG DSAwere detected.
Clinical characteristics
The clinical characteristics of patients grouped according to
complement binding are shown in Table 1. There were no
differences in age at transplantation, donor type and number
of mismatches. In terms of C1q, there were more boys and
fewer congenital anomalies of the kidney and urinary tract
(CAKUT) in the C1q− group than in the C1q+ group. In terms
of immunosuppression at the time of DSA detection, roughly
half of patients were on dual therapy consisting of predniso-
lone and either tacrolimus or mycophenolate mofetil (MMF).
Patients were switched to MMF to minimise calcineurin in-
hibitor toxicity, which is in line with standard clinical practice
at that time [8, 9]. Taking into consideration the small numbers
in the different groups, the differences in medications were
statistically significant in the patients tested for C3d. C3d+
patients were more likely to be on MMF than on tacrolimus
when on dual therapy [6/8 (75%) C3d+ vs. 7/21 (33%) C3d−;
Table 2 Clinical characteristics
of patients according to assay
results for C1q and C3d
Clinical characteristics of patients C1q C3d
C1q+ (n = 32) C1q− (n = 33) C3d+ (n = 23) C3d− (n = 42)
Time to first DSA (years) 2.6 (0.1–4.9) 0.4 (0.1–2.1) 2.3 (0.1–4.1) 0.4 (0.1–3.1)
Sex, male 21 (66%)** 27 (82%)** 15 (65%) 33 (79%)
Cause of end-stage kidney disease
CAKUT 22 (69%)* 12 (36%)* 15 (65%) 19 (45%)
Glomerulonephritis 3 (9%) 5 (15%) 3 (13%) 5 (12%)
Others 7 (22%) 16 (48%) 5 (22%) 18 (43%)
Mismatches 2 (2–3) 2 (2–3) 2 (2–3) 2 (2–3)
Age of transplant (years) 7.2 (4.7–10.5) 11.1 (5.6–13.9) 7.3 (5.1–10.1) 10.3 (5.2–13.8)
Donor type LD 20 (63%) 17 (52%) 14 (61%) 23 (55%)
Medication:
Pred/Aza/Tac 7 (24%) 11 (35%) 3 (18%)* 15 (35%)*
Pred/Tac/MMF 5 (17%) 4 (13%) 4 (24%)* 5 (12%)*
Pred/MMF 8 (28%) 5 (26%) 6 (35%)* 7 (16%)*
Pred/Tac 6 (21%) 10 (32%) 2 (12%)* 14 (33%)*
Tac/MMF 1 (3%) 1 (3%) 0 2 (5%)
Tac 1 (3%) 1 (5%)
MMF 1 (3%) 1 (5%)
*, ** Significantly different at: *p < 0.05, **p < 0.005. Results are not significantly different unless otherwise
stated
Results in table are presented at the median with the interquartile range (IQR) in parenthesis or as the frequency
(number) with the percentage in parenthesis, as appropriate
CAKUT, Congenital anomalies of the kidney and urinary tract; LD, living donor;; Pred, prednisolone; Aza,
azathioprine; Tac, tacrolimus; MMF, mycophenolate mofetil
Fig. 2 Corresponding IgG mean fluorescence intensity (MFI) values
according to the complement binding results. Horizontal bars represents
groups compared. ns Not significant
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p < 0.05]. The proportion of patients on azathioprine was
higher in the C3d− group than in the C3d+ group, compared
toMMF for patients on triple therapy [3/7 (48%) C3d+ vs. 15/
20 (75%) C3d−; p < 0.05].
Clinical outcomes
The primary outcome was a 50% reduction in eGFR, which
was used as a surrogate marker of long-term renal allograft
survival (Fig. 3). Patients who were DSA− from the previous
study were used in the present study for comparative pur-
poses. There was no difference in eGFR decline between
C1q+ and C1q− patients [median time to primary event 5.9
vs. 6.4 years, respectively; p = 0.58; hazards ratio (HR) 0.74;
95% confidence interval (CI) 0.30–1.81]. On the other hand,
C3d+ patients had a significantly faster eGFR decline than
C3d− patients (5.6 vs. 6.5 years, p = 0.04; HR 0.38; 95% CI
0.15–0.97). Combining the C1q and C3d results did not im-
prove the significance of the complement binding assays
(C1q+/C3d+ vs. C1q−/C3d−: 5.2 vs. 6.6 years respectively,
p = 0.09; HR 0.42; 95%CI 0.15–1.14) (ESM Fig. 1). Counter-
intuitively, single binding of only either C1q or C3d (C1q+/
C3d− and C1q−/C3d+) did not adversely affect renal allograft
function.
Histology findings based on complement binding results
are shown in Table 3. C1q+ patients were associated with
increased episodes of tubulitis [0.75 ± 0.18 (C1q+) vs.
0.25 ± 0.08 (C1q−) episodes per patient; p < 0.05]. Patients
who were positive for complement binding showed a higher
proportion of C4d binding on biopsies, which reached statis-
tical significance for the C3d results [48% (C3d+) vs. 20%
(C3d−); p < 0.05). There was no difference in AMR (compos-
ite of glomerulitis, pericapillaritis and glomerular double
contouring) or presence of CD20 aggregates.
Longitudinal analysis
Based on the better correlation with outcome obtained with
the C3d assay, testing for C3d was extended to all DSA+ sera.
Of the 65 patients enrolled in the study, 33 had multiple DSA+
sera available for testing (median 3, IQR 3–4 sera per patient).
Ten patients remained C3d−; four patients converted from
negative to positive; 12 patients were C3d+ throughout; four
patients were intermittently positive; three patients were pos-
itive at the start, then became negative. The latter three pa-
tients had low C3d MFI of 1979 (HLA-B), 1750 (HLA-DR)
and 1386 (HLA-DQ). Four patients received intravenous ri-
tuximab—three for chronic AMR and one for post-transplant
lymphoproliferative disorder. C3d remained positive in three
patients who received intravenous rituximab; the remaining
patient had low C3d+ DSA (MFI 1386) which became nega-
tive after receiving an intravenous infusion of rituximab and
increasing immunosuppression to prednisolone, tacrolimus
andMMF. Over time, the increase in C3dMFI correlated with
increasing IgG MFI (co-efficient 1.5, ±1.1 units; p < 0.0001).
There was no correlation between eGFR and C3d MFI
(1.0 ± 1.5 ml/min/1.73 m2; p = 0.9).
Discussion
We investigated the utility of complement binding assays to
further stratify DSA+ patients at risk of worse renal allograft
outcomes. In vitro, a larger proportion of DSA fixed C1q
compared to C3d (49 vs. 35%). Complement positivity corre-
lated poorly with IgG MFI, and a clear threshold could not be
defined. C1q+ DSA were associated with a higher risk of
tubulitis, but the long-term renal allograft function of these
patients was not significantly different to those with C1q−
DSA. C3d+ DSA were associated with more C4d staining
on ‘for-cause’ biopsies and significantly worse renal allograft
function.
We hypothesised that patients producing complement-
fixing DSA would have a worse allograft outcome because
Fig. 3 Time to event (defined as a 50% reduction from baseline
estimated glomerular filtration rate (eGFR) according to DSA−, DSA+/
C1q− and DSA+/C1q+ (a) and DSA−, DSA+/C3d− and DSA+/C3d− (b)
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of the implication that in vivo, binding to the allograft endo-
thelium would enable recruitment of additional immune acti-
vation pathways through activation of the complement cas-
cade. The ability of antibody to activate the complement cas-
cade depends on the IgG subtype and corresponding Fc por-
tion [10], in addition to the target antigen density and proxim-
ity of multiple target HLA molecules to allow cross-linking
and subsequent binding of C1q [10]. This in turn triggers the
classical complement pathway through a series of regulated
intermediate steps, leading to the formation of C4bC2b, which
catalyses the breakdown of C3 into its active components
[11]. C3 is the converging point of three complement path-
ways, ultimately leading to the generation of C5b-9, the mem-
brane attack complex (MAC) and cell lysis. The breakdown
products of C4b and C3 include C4d and C3d, respectively,
which covalently bind to cell membranes [11]. Therefore,
in vitro tests have been designed to probe the complement
binding capabilities of DSA at the check-points C1q, C4d
and C3d [12]. Fixing of C1q is a pre-requisite for initiation
of the complement cascade. C3d itself is dissociated from IgG,
i.e. C3d is not bound to antibody but rather is attached to cell
membranes or complement receptors. Interestingly, we
showed that 41% of antibodies positive for C1q binding do
not concomitantly fix C3d, despite agreement between the
pan-IgG kits. Whether this is a specific difference in function-
al characteristics of the antibody detected, a reflection of an-
tibody titre or a difference inherent in the assays needs ad-
dressing in the future.
This study focused on DSA+ patients initially identified
using the pan-IgG LABScreen SAB. We therefore cannot rule
out patients who might have tested DSA IgG+ using the al-
ternative Immucor SAB assay. However, our laboratory expe-
rience and a review of the literature suggests agreement rates
of 90% [13]. In our subset of C1q−/C3d+ patients, there was
only 50% agreement between kits, i.e. additional IgG+ pa-
tients were identified on the Immucor SAB. However, long-
term renal allograft function was not worse. Therefore, the
discrepancy in results could be due to kit-related factors, such
as the presence of denatured HLA antigen or the detection of
potentially non-significant antibody [14]. In addition,
complement-binding DSA tended to be detected later post-
transplant, in agreement with previous studies showing that
patients with early onset DSA and AMR had better responses
to treatment and favourable clinical outcomes [15–17].
This study is limited by its retrospective nature and by the
relatively small number of patients, which precluded further
multi-variable survival analysis. In addition, rejection and re-
duced allograft function was more prevalent among the group
of patients for whom sera were unavailable for testing, whom
we hypothesised would have complement-binding DSA.With
these caveats, our data do suggest an association between
C1q+ DSA and increased episodes of acute tubulitis. This
was also reported by Lefaucheur et al. using a non-
supervised principal component analysis examining IgG sub-
classes and C1q [18]. C4d staining in vivo correlatedwith C3d
testing in vitro which is downstream of C4 in the complement
cascade. In vivo C3d staining has rarely been reported in the
literature. One histological study of biopsies during acute al-
lograft rejection showed C3d peritubular capillary staining in
30% of samples and increased renal allograft loss in the C3d+
patients [19]. MAC deposition has been shown in patients
with HLA incompatible transplants, but its role in non-
sensitised de novo AMR has not been studied [20]. MAC
deposition results in cell lysis, although sublytic concentra-
tions also can induce pro-inflammatory changes in glomerular
cells and endothelial mesenchymal transition of tubular cells
[21, 22].
The results of our study are in concordance with those of a
recently published study in paediatric renal transplant recipi-
ents that also concomitantly assessed C1q and C3d binding
[23]. Both studies showed a lower proportion of C3d binding
and better prognostic predictability with the C3d assay.
Comoli et al. also showed that patients could progress from
C1q−/C3d− to C1q+/C3d+ and from C1q+/C3d− to C1q+/
C3d+. Some patients were intermittently positive for comple-
ment binding associated with a low MFI of <2000 [23]. The
Table 3 Histological findings
based on complement binding
results
Histological findings C1q C3d
C1q+ (n = 32) C1q− (n = 33) C3d+ (n = 23) C3d− (n = 42)
Tubulitis 0.75 ± 0.18* 0.25 ± 0.08* 0.65 ± 0.22 0.42 ± 0.22
Vasculitis 0* 0.18 ± 0.09* 0.1 ± 0.07 0.16 ± 0.07
C4d 13 (39%) 6 (19%) 10 (48%)* 9 (20%)*
AMR 8 (24%) 3 (9%) 5 (24%) 6 (14%)
CD20 10 (30%) 9 (28%) 7 (33%) 12 (27%)
*Significantly different at p < 0.05. Results are not significantly different unless otherwise stated
Results in the table are shown as the mean number of episodes per patient ± standard error of the mean or as a
number (frequency) with the percentage in parenthesis
AMR, Antibody-mediated rejection
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current studies highlight the complexities of assessing DSA.
MFI has often been used in studies as a quantitative measure
of DSA although there is significant inter-assay variability and
the assay is not licenced clinically as a quantitative measure
[13]. It is also subject to the prozone effect which can give an
artificially low MFI [24]. This can be overcome by dilutional
titering. although this adds additional time and cost factors. In
addition, studies have shown an association between C1q
binding, IgG subtypes and IgG MFI, thus limiting the extra
information obtainable in performing all three assays [25]. In
our study, sera were obtained prospectively as per guidelines
regardless of renal allograft function; as compared to studies
which were done at the time of graft dysfunction and biopsy
‘for cause’ [6, 26]. In addition, our patients had low pre-
transplant HLA antibody sensitisation rates which are not
comparable to those of adult studies which include highly-
sensitised and HLA-incompatible transplants [4, 5, 17]. We
showed that the C3d assay potentially further stratified pa-
tients at the highest risk of renal allograft failure. This is inde-
pendent of IgG MFI as the correlation between C3d and IgG
MFI was poor (adjusted R2 0.11), with a significant overlap of
C3d+ and C3d– patients in the moderate MFI range of be-
tween 1000 and 8000. Nonetheless, the results would be
strengthened by being validated in a prospective study.
In conclusion, our study adds to the evidence of the poten-
tial importance of determining complement binding capabili-
ties when testing for de novo DSA. Of the DSA we detected
49% could bind C1q, and its presence was associated with an
increased proportion of ‘for-cause’ biopsies showing acute
tubulitis, but not with worse long-term outcome. 35% of the
DSA fixed C3d, and these DSA were associated with an in-
creased proportion of ‘for-cause’ biopsies demonstrating pos-
itive C4d histological staining and significantly worse long-
term renal allograft dysfunction. With the increasing financial
pressures on healthcare provision, along with the significant
costs of performing these tests, we believe these data may aid
the decision-making behind the choice of tests used for post-
transplant DSA monitoring.
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